- Home
- GYRE vs RWT Comparison
GYRE vs RWT Comparison
Compare GYRE & RWT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- RWT
- Stock Information
- Founded
- GYRE 2002
- RWT 1994
- Country
- GYRE United States
- RWT United States
- Employees
- GYRE N/A
- RWT N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- RWT Real Estate Investment Trusts
- Sector
- GYRE Health Care
- RWT Real Estate
- Exchange
- GYRE Nasdaq
- RWT Nasdaq
- Market Cap
- GYRE 755.7M
- RWT 734.0M
- IPO Year
- GYRE N/A
- RWT 1995
- Fundamental
- Price
- GYRE $8.19
- RWT $5.30
- Analyst Decision
- GYRE Strong Buy
- RWT Buy
- Analyst Count
- GYRE 2
- RWT 8
- Target Price
- GYRE $17.00
- RWT $7.00
- AVG Volume (30 Days)
- GYRE 60.0K
- RWT 1.2M
- Earning Date
- GYRE 11-07-2025
- RWT 10-29-2025
- Dividend Yield
- GYRE N/A
- RWT 13.74%
- EPS Growth
- GYRE N/A
- RWT N/A
- EPS
- GYRE 0.04
- RWT N/A
- Revenue
- GYRE $107,265,000.00
- RWT $120,897,000.00
- Revenue This Year
- GYRE $15.25
- RWT N/A
- Revenue Next Year
- GYRE $33.14
- RWT $30.20
- P/E Ratio
- GYRE $211.54
- RWT N/A
- Revenue Growth
- GYRE 2.13
- RWT N/A
- 52 Week Low
- GYRE $6.11
- RWT $4.68
- 52 Week High
- GYRE $19.00
- RWT $7.29
- Technical
- Relative Strength Index (RSI)
- GYRE 59.01
- RWT 41.07
- Support Level
- GYRE $7.12
- RWT $5.12
- Resistance Level
- GYRE $7.42
- RWT $5.77
- Average True Range (ATR)
- GYRE 0.34
- RWT 0.17
- MACD
- GYRE 0.04
- RWT 0.00
- Stochastic Oscillator
- GYRE 94.82
- RWT 32.86
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About RWT Redwood Trust Inc.
Redwood Trust Inc is a real estate investment trust focused on different areas of housing credit. The company operates in three segments: Sequoia Mortgage Banking includes mortgage loan conduit that acquires residential consumer loans from third-party originators for sale to whole loan buyers and securitization; CoreVest Mortgage Banking segment includes consists of a platform that originates residential investor loans for securitization, sale, or transfer into Redwood Investments portfolio; and Redwood Investments segment consists of organic investments sourced through mortgage banking operations, including securities retained from Sequoia and CoreVest securitization activities. It derives maximum revenue from Redwood Investments segment.